Comparision of two different doses of Nalbuphine as adjuvant in spinal anaesthesia in Urology cases

Comparitive study of two different doses of Nalbuphine as an adjuvant to intrathecal Bupivacaine in percutaneous Nephrolithotomy cases

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/059266

Enrollment

Registered

2023-10-30

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: spinal anesthesia: Intrathecal Bupivacaine 3 ml plus 1mg (0.5ml)of Nalbuphine, once. Control Intervention1: Spinal Anesthesia: Intrathecal Bupivacaine 3 ml plus 0.5mg of Nalbuphine, onc

Eligibility

Inclusion criteria

Inclusion criteria: ASA Physical status 1 and 2

Exclusion criteria

Exclusion criteria: Patients who have Coagulopathy Patients with anatomic abnormalities Localised Infection Allergy to study Medication Patients who are unable to comprehend the protocol or communicate pain scores or need for analgesia

Design outcomes

Primary

Measure	Time frame
Increase in the time of rescue analgesic requirement The onset of sensory blockade is similar in both groupsTimepoint: With in 8 hrs of surgery	—

Secondary

Measure	Time frame
Delayed motor regression timeTimepoint: With in 8 hrs after surgery	—

Countries

India

Contacts

Public ContactDr Bharathi B

Saveetha Medical college

doctor.bharathi@gmail.com9566584767

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026